Tina S. Nova, Ph.D., serves as President of Veracyte’s CLIA U.S. Business. In this role, she leads all aspects – market development, product marketing, reimbursement, sales and lab operations – of the company’s broad menu of diagnostic tests that are performed in its laboratories, serving physicians and their patients in the United States. Dr. Nova is a life science industry veteran with extensive experience building and leading novel genomics-based businesses. She most recently served as Veracyte’s General Manager of Thyroid and Urologic Cancers, and previously served as Chief Executive Officer of Decipher Biosciences prior to Veracyte’s March 2021 acquisition of the company. Prior to that, she was President and Chief Executive Officer of Molecular Stethoscope, Inc., a molecular diagnostics company, and before that served as Senior Vice President and General Manager of Illumina’s oncology business unit. From 2000 to 2014, Dr. Nova was a Co-founder and Director, President and Chief Executive Officer of Genoptix Medical Laboratory, which was purchased by Novartis Pharmaceuticals Corporation. She has also held senior positions with Nanogen, Inc., Ligand Pharmaceuticals, Inc. and Hybritech, Inc. Dr. Nova currently serves on the board of directors for Arena Pharmaceuticals and Exagen, and previously served on Veracyte’s board of directors. She holds a B.S. degree in Biological Sciences from the University of California, Irvine, and a Ph.D. in Biochemistry from the University of California, Riverside.
Tina S. Nova, Ph.D.
President, CLIA U.S. Business